High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.

J Transl Med · 2024 · PMC10877900 · PMID 38378604

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unfavorable trendno p-value reported

We found that patients who showed an unfavorable trend of mutation abundances of KRAS, TP53, and/or CDKN2A at the second or third measurement mostly experienced PD within 4 months of chemotherapy.

also in 30 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.